RESUMEN
Purpose: Chronic bronchitis (CB), a chronic obstructive pulmonary disease (COPD) phenotype defined by persistent mucus hypersecretion and cough, is associated with poor quality of life, exacerbations, and lung function impairment. Bronchial Rheoplasty (BR) delivers non-thermal pulsed electric fields to airway epithelium and submucosa. Preliminary studies demonstrated reduced airway goblet cell hyperplasia and symptom improvement in response to BR. This study aimed to further assess the safety and clinical feasibility of BR in the setting of CB. Patients and Methods: This 3-center, single-arm study evaluated the safety and feasibility of BR in Canadian patients. The major inclusion criteria were the sum of CAT first 2 questions (cough and mucus) ≥ 7 out of 10 and FEV1 ≥ 30% predicted. Right-sided airways were treated first; left, 1 month later. Serious adverse events (SAEs) were tabulated through 12 months. Outcomes were evaluated using the SGRQ and CAT. Results: Ten patients with CB were enrolled and followed for 12 months. The BR procedure was successful in all patients (mean age 69 ± 5.8 years, post-BD FEV1 77.1 ± 28.3, SGRQ 56.2 ± 8.8, CAT 25.4 ± 4.7). Only one SAE, a COPD exacerbation 13 days following the BR procedure, was considered device related. No additional SAEs occurred through 12 months, and 90% of the patients were CAT responders (≥ 2-point improvement) at 3 and 6 months. Similar results were observed in SGRQ. Conclusion: BR was safe and well-tolerated. Meaningful symptom improvement was observed through 12 months, suggesting BR may be a viable treatment option for patients with CB.
Asunto(s)
Bronquitis Crónica , Estudios de Factibilidad , Pulmón , Humanos , Masculino , Femenino , Anciano , Resultado del Tratamiento , Bronquitis Crónica/fisiopatología , Bronquitis Crónica/cirugía , Bronquitis Crónica/terapia , Persona de Mediana Edad , Volumen Espiratorio Forzado , Pulmón/fisiopatología , Pulmón/cirugía , Pulmón/efectos de los fármacos , Factores de Tiempo , Canadá , Recuperación de la Función , Calidad de Vida , Terapia por Estimulación Eléctrica/efectos adversos , Terapia por Estimulación Eléctrica/instrumentación , Terapia por Estimulación Eléctrica/métodos , Bronquios/fisiopatología , Bronquios/cirugía , Encuestas y Cuestionarios , Estudios ProspectivosRESUMEN
A man in his early 70s with a long-standing history of chronic bronchitis presented to our department 3 years ago with debilitating chronic cough and excessive sputum production. He had no previous diagnosis of chronic obstructive pulmonary disease and without evidence of severe respiratory tract infections. Due to his symptom burden and impairments in daily activities, the patient was considered to be an appropriate candidate for bronchial rheoplasty, a novel endoscopic treatment for patients with chronic bronchitis. The patient responded well to bilateral treatment but then experienced symptom recurrence roughly 14 months after completing the initial treatment. In the absence of an alternative explanation for the return of these symptoms, he then underwent uneventful retreatment. The patient, again, reported significant symptom improvement and no adverse effects since retreatment. While further studies are necessary to assess the safety and efficacy of retreatment, the findings from this case are encouraging.
Asunto(s)
Bronquitis Crónica , Bronquitis , Enfermedad Pulmonar Obstructiva Crónica , Masculino , Humanos , Bronquitis Crónica/tratamiento farmacológico , Bronquitis Crónica/cirugía , Bronquios , Retratamiento , Enfermedad Crónica , Bronquitis/complicaciones , Bronquitis/tratamiento farmacológico , Bronquitis/diagnósticoRESUMEN
INTRODUCTION: Chronic bronchitis (CB), a phenotype of chronic obstructive pulmonary disease (COPD) characterised by persistent cough and mucus hypersecretion, is associated with poor outcomes despite guideline-based treatment. Bronchial rheoplasty (BR) with the RheOx system delivers non-thermal pulsed electric fields to the lower airway epithelium and submucosa to reduce mucus producing cells. Early phase clinical trials including 1-year follow-up have demonstrated reduction in airway goblet cell hyperplasia and improvement in CB symptoms. METHODS: The current multicentre observational BR study enrolled 21 patients with CB at six centres in the USA, with bilateral treatment and 2-year follow-up. Entry criteria included elevated cough and sputum scores from COPD Assessment Test (CAT) and forced expiratory volume in one second<80% predicted. Safety was assessed by serious adverse event (SAE) incidence through 24 months. Clinical utility was evaluated using changes in the CAT, the St. George's Respiratory Questionnaire (SGRQ) and by comparing exacerbation rates before and following intervention. RESULTS: No procedure-related or device-related SAEs occurred. Mean (SD) changes from baseline in CAT at 12 and 24 months were -9.0 (6.7) (p<0.0001) and -5.6 (7.1) (p<0.0047) and in SGRQ were -16.6 (13.2) (p<0.0001) and -11.8 (19.2) (p<0.0227), respectively. There was a 34% reduction in moderate and a 64% reduction in severe COPD exacerbation events compared with the year prior to treatment. CONCLUSIONS: This study extends the findings from previous feasibility studies, demonstrating that BR can be performed safely and may significantly improve symptoms and health-related quality of life for patients with CB through 24 months. TRAIL REGISTRATION NUMBER: NCT03631472.
Asunto(s)
Bronquitis Crónica , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Bronquitis Crónica/cirugía , Estudios de Factibilidad , Calidad de Vida , Progresión de la Enfermedad , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológicoRESUMEN
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is associated with disabling respiratory symptoms including dyspnea, frequent exacerbations and chronic bronchitis. The currently available pharmacological and non-pharmacological therapies have limited efficacy, necessitating the development of interventional strategies, many of them endoscopic. STATE OF THE ART: Endoscopic lung volume reduction has markedly increased over recent years, principally as regards the endobronchial valves currently used in routine care. Indeed, multiple randomized trials have demonstrated a significant clinical benefit in a selected population identifiable due to the absence of interlobar collateral ventilation. Other endoscopic volume reduction techniques (polymers, thermal vapor, spirals) shall require additional studies before being considered as options in routine care. Targeted lung denervation (TLD) has aroused interest as a means of reducing exacerbations in the early phases of relevant studies. Endobronchial techniques (bronchoscopic cryospray, bronchial rheoplasty) are still at a very early stage of development, which is aimed at reducing the symptoms of chronic bronchitis. OUTLOOK: Aside from endobronchial valves, which are currently employed in routine care, all the above-mentioned endoscopic techniques require additional studies in order to determine their benefit/risk balance and to identify the population that would benefit the most. CONCLUSIONS: Endoscopic treatments constitute a major avenue of research and innovation in the therapeutic management of COPD. Inclusion of patients in disease registries and clinical trials remains essential, the objective being to gauge the interest of these treatments and their future role in everyday COPD management.
Asunto(s)
Bronquitis Crónica , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Bronquitis Crónica/complicaciones , Bronquitis Crónica/cirugía , Broncoscopía/métodos , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/terapia , Pulmón , Neumonectomía/métodosRESUMEN
Until now, interventional therapies for patients with chronic obstructive pulmonary disease have been available in the form of lung volume reduction procedures as end-stage options. Currently, the range of indications is expanding to include earlier stages of the diseases. Lung denervation is available for moderate COPD, and patients with chronic bronchitis are being evaluated for endoscopic goblet cell ablation. Rheoplasty, metered spray cryo technique, and Karakoca resector balloon are used for this indication. But also, for patients with severe uncontrolled asthma, several techniques are available today. In addition to thermoplasty as a long-proven procedure, new and currently under investigation is the targeted lung denervation.Most of these techniques are currently being tested in large pivotal trials and it will soon become clear in which phenotype which technique will be used in the different forms and stages of obstructive diseases. The current paper presents the techniques and the currently available literature.
Asunto(s)
Asma , Bronquitis Crónica , Enfermedad Pulmonar Obstructiva Crónica , Asma/terapia , Bronquitis Crónica/cirugía , Broncoscopía/métodos , Humanos , Neumonectomía , Enfermedad Pulmonar Obstructiva Crónica/cirugíaRESUMEN
Rationale: Chronic bronchitis (CB) is characterized by productive cough with excessive mucus production, resulting in quality-of-life impairment and increased exacerbation risk. Bronchial rheoplasty uses an endobronchial catheter to apply nonthermal pulsed electrical fields to the airways. Preclinical studies have demonstrated epithelial ablation followed by regeneration of normalized epithelium.Objectives: To evaluate the feasibility, safety, and initial outcomes of bronchial rheoplasty in patients with CB.Methods: Pooled analysis of two separate studies enrolling 30 patients undergoing bilateral bronchial rheoplasty was conducted. Follow-up through 6 months (primary outcome) and 12 months included assessment of adverse events, airway histology, and changes in symptoms using the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test and St. George's Respiratory Questionnaire (SGRQ).Measurements and Main Results: Bronchial rheoplasty was performed in all 30 patients (63% male; mean [SD] age, 67 [7.4]; mean [SD] postbronchodilator FEV1, 65% [21%]; mean [SD] COPD Assessment Test score 25.6 [7.1]; mean [SD] SGRQ score, 59.6 [15.3]). There were no device-related and four procedure-related serious adverse events through 6 months, and there were none thereafter through 12 months. The most frequent nonserious, device- and/or procedure-related event through 6 months was mild hemoptysis in 47% (14 of 30) patients. Histologically, the mean goblet cell hyperplasia score was reduced by a statistically significant amount (P < 0.001). Significant changes from baseline to 6 months in COPD Assessment Test (mean, -7.9; median, -8.0; P = 0.0002) and SGRQ (mean, -14.6; median, -7.2; P = 0.0002) scores were observed, with similar observations through 12 months.Conclusions: This study provides the first clinical evidence of the feasibility, safety, and initial outcomes of bronchial rheoplasty in symptomatic patients with CB.Clinical trial registered with www.anzctr.org.au (ACTRN 12617000330347) and clinicaltrials.gov (NCT03107494).
Asunto(s)
Técnicas de Ablación/métodos , Bronquios/cirugía , Bronquitis Crónica/cirugía , Anciano , Bronquitis Crónica/fisiopatología , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Volumen Espiratorio Forzado , Humanos , Masculino , Estudios Prospectivos , Calidad de Vida , Factores de Tiempo , Resultado del TratamientoRESUMEN
Unilateral agenesis of the pulmonary artery (UAPA) is a rare congenital anomaly. This report describes a 52-year-old female who gave a long history of chronic, recurrent, left-sided pulmonary infections related to UAPA. For many years, she was managed medically but the infection continued to recur. She eventually underwent left pneumonectomy and made a good recovery.
Asunto(s)
Bronquitis Crónica/etiología , Neumonía/etiología , Arteria Pulmonar/anomalías , Malformaciones Vasculares/complicaciones , Bronquitis Crónica/diagnóstico , Bronquitis Crónica/cirugía , Femenino , Humanos , Persona de Mediana Edad , Neumonectomía , Neumonía/diagnóstico , Neumonía/cirugía , Arteria Pulmonar/diagnóstico por imagen , Recurrencia , Tomografía Computarizada por Rayos X , Malformaciones Vasculares/diagnósticoRESUMEN
Carbohydrate antigen 19-9 (CA19-9) is the most frequently applied serum tumor marker for diagnosis of cancers in the digestive organs. However, some patients with benign diseases can have elevated serum levels of CA19-9 as well. The current study presents a 55-year-old female who was admitted to our hospital for further evaluation of a nodular cavity shadow in the right lower lobe and clarification of the cause of the marked elevation of serum CA19-9 levels. Abdominal MRI and gastrointestinal endoscopy did not find any malignancy. As lung cancer cannot be excluded in this patient, a video-assisted thoracoscopic surgery was carried, intraoperative and postoperative biopsy analysis both suggested chronic bronchitis with fungal infection (due to Histoplasma capsulatum or Penicillium marneffei) and organization. Immunohistochemistry showed marked positive staining for CA19-9 in the damaged lung tissue. The CA19-9 levels quickly returned to the normal range following lobe resection. Therefore, the marked elevation of serum CA19-9 levels, in this case, may have resulted from the chronic bronchitis with fungal infection.
Asunto(s)
Bronquitis Crónica/sangre , Antígeno CA-19-9/sangre , Histoplasmosis/sangre , Enfermedades Pulmonares Fúngicas/sangre , Biomarcadores/sangre , Biopsia , Bronquitis Crónica/diagnóstico , Bronquitis Crónica/microbiología , Bronquitis Crónica/cirugía , Femenino , Histoplasma/patogenicidad , Histoplasmosis/diagnóstico , Histoplasmosis/microbiología , Histoplasmosis/cirugía , Humanos , Inmunohistoquímica , Enfermedades Pulmonares Fúngicas/diagnóstico , Enfermedades Pulmonares Fúngicas/microbiología , Enfermedades Pulmonares Fúngicas/cirugía , Persona de Mediana Edad , Penicillium/patogenicidad , Neumonectomía/métodos , Valor Predictivo de las Pruebas , Cirugía Torácica Asistida por Video , Factores de Tiempo , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Regulación hacia ArribaRESUMEN
OBJECTIVE: To study the feasibility of CT pulmonary function imaging as a tool for screening target lung lobes in bronchoscopic lung volume reduction. METHODS: A total of 31 patients with chronic bronchitis were included in the study and all of them underwent lung function tests, chest HRCT, and pulmonary ventilation-perfusion radionuclide scan. According to the lung function results, the patients were divided into 2 groups: 9 with normal lung function (normal group) and 22 with obstructive ventilatory dysfunction (emphysema group). The correlation between HRCT visual score, CT imaging parameters of lung function and pulmonary function results were analyzed. For each lung lobe, the correlation and difference between average CT values, pixel index (PI), and ventilation perfusion ratio (V/Q) were also analyzed to explore the reliability of CT lung function imaging for determining regional non-functional "target area" in candidate patients for bronchoscopic lung volume reduction. RESULTS: There was no correlation between HRCT visual scores and lung function test parameters (RV/TLC and FEV1/FVC) However, CT lung function imaging evaluation showed a good correlation with the lung function test parameters. For individual lung lobes, the average CT value and the pixel index (PI = -910 HU) were correlated with the corresponding lobe perfusion of the total lung perfusion percentage ratio. CONCLUSIONS: CT pulmonary function imaging results were objective, and had a good correlation with lung function tests and lung ventilation-perfusion scan results, which may be useful as a tool for screening target lung lobes in bronchoscopic lung volume reduction.